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Abstract
Background: The role of cytokines in establishing specific transcriptional programmes in innate immune cells has
long been recognized. However, little is known about how these extracellular factors instruct innate immune cell
epigenomes to engage specific differentiation states. Human monocytes differentiate under inflammatory
conditions into effector cells with non-redundant functions, such as dendritic cells and macrophages. In this
context, interleukin 4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF) drive dendritic cell
differentiation, whereas GM-CSF alone leads to macrophage differentiation.
Results: Here, we investigate the role of IL-4 in directing functionally relevant dendritic-cell-specific DNA
methylation changes. A comparison of DNA methylome dynamics during differentiation from human monocytes to
dendritic cells and macrophages identified gene sets undergoing dendritic-cell-specific or macrophage-specific
demethylation. Demethylation is TET2-dependent and is essential for acquiring proper dendritic cell and
macrophage identity. Most importantly, activation of the JAK3-STAT6 pathway, downstream of IL-4, is required for
the acquisition of the dendritic-cell-specific demethylation and expression signature, following STAT6 binding. A
constitutively activated form of STAT6 is able to bypass IL-4 upstream signalling and instruct dendritic-cell-specific
functional DNA methylation changes.
Conclusions: Our study is the first description of a cytokine-mediated sequence of events leading to direct
gene-specific demethylation in innate immune cell differentiation.
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Background
DNA methylation plays a fundamental role in differenti-
ation by driving and stabilizing gene activity states during
cell-fate decisions. DNA methylation maps at different
steps of haematopoietic differentiation have yielded essen-
tial information about the different regulatory roles of
DNA methylation in the various genomic regions (pro-
moters, enhancers, etc.) that contribute to cell identity
[1, 2] and support the notion that DNA methylation
changes are tightly coupled to transcription factors (TFs)
[3, 4]. However, we know little about the mechanisms
directing the targeted deposition or erasure of DNA methy-
lation, and the upstream mechanisms associated with them.
Terminal differentiation from monocytes (MOs) to den-
dritic cells (DCs), macrophages (MACs) and other related
cell types, like osteoclasts (OCs), represent ideal biological
processes to investigate the mechanisms by which extracel-
lular stimulation is translated in nuclear epigenetic control.
Mononuclear phagocytes are crucial components of a wide
range of important biological functions, such as the main-
tenance of homeostasis of several tissues, coordination of
the innate immune response, and participation in adaptive
immunity to proper activation, regulation and resolution
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[5]. These cells express high levels of the methylcytosine
dioxygenase TET2 [6, 7], a key enzyme that successively ox-
idizes 5-methylcytosines, generating intermediate forms in
the pathway towards demethylation [8], a process that takes
place in these differentiation processes [6, 9]. In addition,
the sets of TFs and upstream signalling pathways in DC
and MAC differentiation have been well studied. This is
useful for investigating the interplay between DNA methy-
lation changes and TFs. By examining the differentiation of
these closely related cell types, we can dissect the specific
role and relationship between TFs and upstream signalling
pathways and downstream interacting DNA methylation-
related enzymes.
MOs, in response to inflammatory signals, such as those
associated with bacterial infection [10], extravasate and
are directed to inflamed peripheral tissues, where they ter-
minally differentiate into MACs and/or DCs. This process
occurs locally and is driven and determined by microenvi-
ronmental stimuli [11]. Although closely related, MO-
derived DCs and MACs exert a variety of non-redundant
functions as a result of activation of specific cell-restricted
transcriptional programmes. MO conversion into in-
flammatory DCs or MACs can be recapitulated in vitro,
by exposing cells to granulocyte macrophage colony-
stimulating factor (GM-CSF)/interleukin 4 (IL-4) or GM-
CSF only, respectively [12]. Human inflammatory DCs
have recently been identified as the in vivo counterpart of
in vitro GM-CSF/IL-4 MO-derived DCs [13]. The GM-
CSF receptor activates JAK2 and downstream mediators
in an inflammatory setting because GM-CSF constitutes a
bona fide danger signal, advising that levels have exceeded
steady state levels in conditions of inflammation or infec-
tion [14]. The IL-4 receptor (IL-4R) signals the activation
of the Janus kinase 3 (JAK3)-STAT6 pathway through its
common γ chain [15], which leads to the development of
immature DCs. Full functionality is achieved in DCs and
MACs upon maturation by engaging surface receptors,
including several pattern recognition receptors such as
Toll-like receptors (TLRs). Acting through outside-to-
inside mechanisms, TLR-mediated signals shape a specific
response aimed at triggering appropriate effector me-
chanisms to eliminate pathogens [16]. Bacteria-derived
lipopolysaccharide (LPS) is a well-known maturation mol-
ecule that acts through TLR4 in MO-derived DCs and
MACs in vitro and in vivo. Despite the recognition of the
role of these and other factors in determining differenti-
ation of these cell types, our knowledge of their contribu-
tion to the acquisition of functionally relevant epigenetic
changes remains limited.
In the present work, we compared the specific DNA
methylation changes associated with the differentiation
from MOs to DCs and from MOs to MACs, as well as
those occurring during the LPS-mediated maturation of
these two cell types. These two differentiation processes
differ only by the exposure of the former to IL-4, and so
enabled us to determine the contribution of this external
signal to DNA methylation changes downstream. Most
changes occurred in the direction of DNA demethylation,
during the differentiation step, whereas very few occurred
during the LPS-mediated activation step. In contrast,
thousands of genes became upregulated or downregulated
in both the differentiation and maturation stages. Some of
the DNA methylation and expression changes were com-
mon to DC and MAC differentiation, whereas others were
specific to each differentiation process. In both cases,
downregulation of TET2 impaired the acquisition of DNA
demethylation and DC/MAC-specific surface markers,
highlighting the functionality of DNA methylation changes.
For a subset of genes, DNA demethylation during the
differentiation step preceded any change in gene expres-
sion, which only occurred at the activation step, suggesting
that DNA methylation changes prepare an epigenetic con-
text suitable for the quick response necessary during activa-
tion. Most importantly, manipulation of the JAK3-STAT6
pathway downstream of IL-4 in DC differentiation altered
the demethylation, expression and STAT6 binding in genes
that are specifically demethylated in DCs. Inhibition of this
pathway allowed demethylation of genes that are exclusively
demethylated in MACs. Consistently, overexpression of a
constitutively active form of STAT6 in MOs in the absence
of IL-4 prevents specific demethylation of MAC genes at
the time that promotes demethylation of DC-specific genes.
This reveals the involvement of the IL-4-JAK3-STAT6
pathway in determining demethylation of DC-specific genes
and preventing demethylation in MAC-specific genes. The
results of our study enable us to identify for the first time
the elements downstream of an external signal, in this case
IL-4 in myeloid immune cells, that are translated into cell-
type-specific functional DNA methylation changes essential
for conferring identity and function.
Results
Differentiation from MOs to DCs and from MOs to MACs
results in cell-type-specific demethylation of thousands of
genes
To dissect the downstream contribution of IL-4 in the ac-
quisition of cell-type-specific DNA methylation changes
in MO-to-DC differentiation, we generated three sets of
matching samples corresponding to MOs from human
peripheral blood, immature DCs (iDCs) and immature
MACs (iMACs), following incubation of MOs with GM-
CSF/IL-4 and GM-CSF only, respectively. Mature DCs
(mDCs) and MACs (mMACs) were then created by ex-
posing iDCs and iMACs to LPS (Fig. 1a). The comparison
of MO-to-DC and MO-to-MAC differentiation allowed
us to isolate the specific effect of IL-4, which is the differ-
ential factor in these two processes. We monitored these
processes by testing different markers using RT-PCR
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(Additional file 1A) and fluorescence-activated cell sorting
(FACS; Additional file 1B). For instance, quantitative RT-
PCR demonstrated upregulation of DC markers (CD209)
and mature DC markers (CD83), and that the level of ex-
pression of CD14 receptor was high in MOs, intermediate
in MACs and low/negative in DCs. FACS analyses re-
vealed that MOs were efficiently differentiated to iDCs
(87–93 %, according to CD209 and CD206) and iMACs
(88 %, according to CD206), and indicated a shift in the
CD83 and CD86 markers that support efficient matur-
ation of these cells, generating 79 % mDCs and 81 %
mMACs (Additional file 1B).
We then performed DNA methylation profiling using
bead arrays that interrogated the DNA methylation sta-
tus of >450,000 CpG sites across the entire genome, cov-
ering 99 % of RefSeq genes. Statistical analysis of the
combined data from the three biological replicates of
MO-to-DC and MO-to-MAC revealed large changes in
DNA methylation during the differentiation step (1,780
and 2,644 CpG sites, respectively). In contrast, only a
few genes displayed differential DNA methylation during
the maturation step (75 and 27 CpG sites for DC and
MAC maturation, respectively) (Fig. 1b and Additional
file 2). In all cases, demethylation prevailed over gains in
DNA methylation, consistent with the results reported
by others [6, 17, 18]. Specifically, demethylated CpG
sites represented 92.9 % of total differentially methylated
CpGs in MO-to-iDC (1,654 CpGs) and 97.8 % of differ-
entially methylated CpG in MO-to-iMAC (2,586 CpGs).
This contrasts with the findings in MO-to-OC differenti-
ation, in which de novo deposition of the DNA methyla-
tion occurs to a similar extent as demethylation [9].
Changes corresponding to the average of three sample
sets were almost identical to the pattern obtained for
each individual sample, highlighting the specificity of the
differences observed (Fig. 1c and Additional file 3A).
The results for DC differentiation were similar to those
reported by Zhang and colleagues [17] (78 % of the
demethylated genes in their study were present in our
own data, Additional file 3B).
Although most CpGs displaying a loss of methylation
were common to the two differentiation processes (Fig. 1d),
a significant fraction of demethylated CpGs were specific to
each process: 14.2 % in MO-to-iDC differentiation (235
genes) and 45.1 % in MO-to-iMAC differentiation (1,167
genes). This implies that DNA demethylation may be im-
portant in determining the differences between the lineages.
Given that IL-4 is the only cytokine to differ between these
two processes, our findings suggest that events downstream
of IL-4 may not only be responsible for the set of genes spe-
cifically demethylated in DCs, but also may directly block
demethylation of those that are specific to MACs.
An analysis of the distribution of CpGs with a significant
decrease in DNA methylation (Fig. 1e) revealed that most
of them map to gene bodies (789 CpGs in MO-to-iDCs and
1,242 in MO-to-iMACs). Over 22 % were located at inter-
genic regions in both differentiation processes. Only about
15 % of the changes occurred near the transcription start
site (TSS) (Fig. 1e). This reinforces the notion that a high
proportion of the changes occur in regulatory regions out-
side promoters, such as enhancers located in the body of
genes. Indeed, using the Illumina annotation tool we deter-
mined that 41 % and 43 % of all demethylated CpG sites in
DC and MAC differentiation, respectively, are located in en-
hancers. The proportion of enhancers was particularly high
in gene bodies and intergenic regions, as expected (Fig. 1e).
Gene ontology (GO) analysis of hypomethylated CpG
revealed significant enrichment [false discovery rate (FDR)
< 0.05] of a variety of functional categories important in
iDC and iMAC differentiation and function, including in-
flammatory and innate immune response (Fig. 1f). These
data suggest that DNA demethylation is targeted to gen-
omic regions that are activated during DC and MAC
differentiation.
As expected, we identified changes in several genes in-
volved in DC and MAC function among the group of
(See figure on previous page.)
Fig. 1 High-throughput DNA methylation comparison between monocytes (MOs) and derived dendritic cells (DCs) and macrophages (MACs).
a Scheme depicting the differentiation system. Peripheral blood MOs were either exposed to granulocyte macrophage colony-stimulating factor
(GM-CSF) + interleukin 4 (IL-4) or GM-CSF only to generate immature DCs and MACs (iDCs and iMACs), respectively. Maturation of these two cell
types to mDCs and mMACs was achieved following incubation with lipopolysaccharide (LPS). b Summary of the DNA methylation changes obtained
when comparing MOs differentiating to iDCs and iMACs, and the maturation towards mDCs and mMACs. Number of CpG sites and genes displaying
significant gain (hyper) or loss (hypo) of DNA methylation changes are shown. c Heatmap of three paired samples (D1, D2 and D3) of MOs and their
derived iMACs, iDCs, mMACs and mDCs. The heatmap includes all CpG-containing probes displaying significant methylation changes (>2-fold or
<0.5-fold change; p < 0.01 and false discovery rate < 0.05) (data in Additional file 2). A scale is shown at the bottom, wherein beta values (i.e. the ratio
of the methylated probe intensity to the overall intensity) range from −3 (lower DNA methylation levels, blue) to +3 (higher methylation levels, red).
d Venn diagram showing the degree of overlap of demethylated CpGs/genes between MO-to-iDC and MO-to-iMAC differentiation. e Distribution of
demethylated CpGs among genomic regions [intergenic, promoter (1,500 and 200 upstream of the transcription start site (TSS), 5′ untranslated region
(UTR), first exon, gene body, and 3′UTR)] for MO-to-iDC and MO-to-iMAC differentiation. The darker insets within each bar indicate the number of sites
annotated as enhancers. f Gene ontology (GO) enrichment analysis of demethylated CpGs in differentiation to iMACs and iDCs showing the most
important categories. g Technical validation of the array data by bisulfite pyrosequencing of modified DNA. Three groups of genes are represented:
demethylated genes specific to iDC differentiation, demethylated genes specific to iMAC differentiation, and genes that are commonly demethylated
in iDC and iMAC differentiation
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demethylated genes in both iDCs and iMACs (Additional
file 4). For example, CSF1R, which codes for the receptor of
the cytokine CSF1 involved in MAC differentiation, and
CCL22, a cytokine that is released by DCs and MACs, were
dramatically demethylated (Additional file 4). iMACs dis-
played specific demethylation on CCL20, an inflammation
chemokine, and IL1B, a cytokine involved in immune and
inflammatory response. We observed very specific demeth-
ylation in DC differentiation at a CpG site in the
gene bodies of DUOX1, an oxidase involved in the
antimicrobial-mediated response, and the signalling
receptor SLAMF1 (Additional file 4).
We then confirmed the robustness of the DNA methy-
lation data in MO-to-iDC and MO-to-iMAC differenti-
ation by bisulfite genomic pyrosequencing of CpG sites.
The selection included genes that were demethylated in
both differentiation processes (CSF1R, CCL22, DUSP5),
and some that were only demethylated in MAC (IL1B,
ARSB, CCL20) or DC differentiation (SLAMF1, DUOX1,
PFAS). In all cases, bisulfite pyrosequencing confirmed
the results of the beadchip array (Fig. 1g and Additional
file 3C) and the demethylation at the aforementioned
genes. It is well established that terminal differentiation
of MOs into DCs/MACs occurs in the absence of cell
division, indicating the occurrence of active DNA de-
methylation mechanisms. To further confirm this, we
measured the extent of DNA replication in our DC and
MAC differentiation experiments by treating cells with
BrdU pulses. Consistent with previous observations [18],
we found no significant differences between the negative
control and the BrdU pulses, implying that DNA methy-
lation changes observed during this period were inde-
pendent of DNA replication (Additional file 1C). The
participation of active DNA demethylation events in this
process is reinforced by the previous findings of our and
other groups [6, 9]. In fact, we observed changes in
5hmC, which is an intermediate oxidized base, resulting
from TET2 activity and leading to active demethylation
(Additional file 3D).
To test the implication and functionality of the methylcy-
tosine dioxygenase TET2 in demethylation during DC and
MAC differentiation, we downregulated TET2 levels using
siRNA transfection against various TET2 sites and com-
pared it to transfection with a control siRNA before DC/
MAC differentiation was induced. TET2 downregulation
partially impaired demethylation of both common and DC/
MAC-specific genes. The impairment was partial because
of a technical aspect related to the inability to achieve the
maximum downregulation of TET2 before the differenti-
ation processes had already started. In addition to the re-
duced demethylation, TET2 downregulation also resulted
in a decrease in surface CD209 and CD83 markers; to-
gether with an increase in CD14 (which is higher in MOs
than in DCs and MACs) (Additional file 5), demonstrating
the functionality of DNA demethylation during these two
processes.
Expression changes and their relationship with DNA
demethylation in MAC and DC differentiation and
maturation
To further investigate the functionality of DNA methyla-
tion changes, we generated expression profiles for the
same cell types (MOs and derived iDCs, iMACs, mDCs
and mMACs). We noted large changes in expression in
both processes. Specifically, we observed upregulation of
2,920 and 3,095 genes and downregulation of 1,513 and
1,476 genes during the differentiation of MOs to iDCs
and to iMACs, respectively (>2-fold change or <0.5-fold
change; p-value < 0.01; FDR < 0.05) (Fig. 2a). We also
identified large changes in the maturation process,
whereby 927 and 1,461 genes were upregulated, and
1,961 and 2,829 were downregulated in the maturation
from iDCs and iMACs to mDCs and mMACs, respect-
ively, after LPS-mediated activation (Fig. 2a). Unlike
changes in DNA methylation, which occurred primarily
in the direction of demethylation and were concentrated
in the differentiation of MOs to iDCs and iMACs, expres-
sion changes occurred in the direction of upregulation
and downregulation, and large changes were observed
during differentiation and maturation. A high proportion
of expression changes were common to the processes of
differentiation into DCs and MACs (Fig. 2b). Specifically,
73.12 % and 68.98 % of the upregulated genes and 72.24 %
and 74.05 % of the downregulated genes were common to
MO-to-iDC and MO-to-iMAC differentiation, respect-
ively, whereas 54.37 % and 34.49 % of the upregulated
genes and 61.09 % and 42.88 % of the downregulated
genes were common to the two maturation processes.
To investigate the relationship between DNA methyla-
tion and expression changes, we compared the two data
sets, focusing on genes that underwent significant de-
methylation. We found that DNA demethylation events
were associated with both gene upregulation and down-
regulation (Fig. 2c), although most genes that became
demethylated were overexpressed (70.4 % for MO-to-
iDC and 67.1 % for MO-to-iMAC). We also examined
whether the location of a given CpG site was related to
the effects on expression. CpGs located in the TSS200
and the first exon had the strongest association between
demethylation and overexpression (Fig. 2d) for both
MO-to-iDC and MO-to-iMAC. Analysing the list of
genes that were both demethylated and overexpressed
during the differentiation step revealed the enrichment
of categories of genes that are functionally relevant to
DC and MAC biology (Additional file 6). For instance,
we observed that genes in the inflammasome pathway
that leads to IL1-mediated inflammation (including
PYCARD, IL1B and IL1A, which act together during the
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MAC innate response [19]) were demethylated and overex-
pressed during MAC differentiation. The inflammasome
sensor protein gene AIM2 [20] was also demethylated dur-
ing MAC differentiation and overexpressed in the MAC
maturation step, strongly suggesting the need for additive
signals to trigger this supramolecular inflammatory system.
As mentioned above, most DNA methylation changes
occur at the differentiation level, both for DC and MAC
differentiation, whereas large expression changes occur
at the activation step, suggesting that a proportion of
genes may undergo DNA methylation changes before
their expression levels change. Indeed, we identified a
set of genes for DC and MAC differentiation/maturation
that became demethylated during differentiation but
were only overexpressed at the maturation level (Fig. 2e),
as if demethylation were priming these genes for upreg-
ulation for when they need to be expressed, that is, for
when DCs or MACs encounter a compound such as
LPS. Some of these genes were common to DCs and
MACs, but others were specific to each cell type (Fig. 2f ).
Among these genes we identified some like IL1B and
CCL20 that undergo DNA demethylation during MAC
differentiation, but only achieve overexpression in MACs
following LPS treatment (Fig. 2g) (Additional file 6). In
such cases, time-course analysis of histone modifications
like H3K27me3 and H3K9me3 revealed that changes in
these marks also precede LPS-mediated stimulation
(Fig. 2h and Additional file 7), suggesting that other
regulatory elements are directly responsible for activation
of these genes once the chromatin context is suitable. Inter-
estingly, the increase in these two heterochromatic marks
took place in DCs, and not in MACs, where expression
does not increase upon LPS-mediated stimulation.
Other genes had different relationships with DNA methy-
lation changes, suggesting a variety of functional conse-
quences associated with DNA demethylation observed at
the differentiation step (Additional file 7).
Inhibition of the JAK3-STAT6 pathway impairs DNA
methylation and expression changes of DC-specific genes
and is a positive switch for changes at MAC-specific
genes
IL-4 signalling is crucial and indispensable to the devel-
opment of human MO-derived DCs. One of the most
important outcomes of our DNA methylation analysis
was the identification of a subset of genes that are spe-
cifically demethylated in DC differentiation in response
to IL-4. To address the role of IL-4 in driving these DC-
specific DNA methylation changes, we studied the con-
tribution of signalling mediators downstream of IL-4R.
Membrane-bound type I IL-4R activates the tyrosine
kinase JAK3, which phosphorylates STAT6 at Tyr641,
leading to its translocation to the nucleus and binding to
target genes [21–23] (Fig. 3a). To examine the role of
the IL-4-JAK3-STAT6 pathway in the acquisition of DC-
specific DNA methylation and expression changes, we
first tested the impact of JAK3 inhibition on the regula-
tion of the aforementioned genes. To this end, we first
used a JAK3-selective inhibitor, PF-956980 [24]. We dif-
ferentiated MOs to DCs and MACs with two different
concentrations of PF-956980 to select the conditions
under which it is active. STAT6 phosphorylation, which
renders STAT6 into its active form, is only present
under the conditions for DC differentiation and not for
MAC differentiation (when IL-4 is absent). As expected,
STAT6 phosphorylation disappeared following JAK3 in-
hibition with 400 nM and 1,000 nM PF-956980 (Fig. 3b).
In the case of MACs, we did not observe STAT6 phos-
phorylation, given the lack of stimulation of JAK3, and
therefore the addition of PF-956980 did not make any
difference (Fig. 3b). Treatment with PF-956980 affected
the presence of the surface markers CD209 and CD83
during GM-CSF/IL-4-mediated differentiation to DCs
(Fig. 3c and Additional file 8), resulting in the generation
of profiles closer to those displayed by MACs. This
(See figure on previous page.)
Fig. 2 Comparison between methylation and expression data for macrophage (MAC) and dendritic cell (DC) differentiation and maturation.
a Heatmap of significant changes between monocyte (MOs)-to-immature DC (iDC) and MO-to-immature MAC (iMAC) differentiation (left) and two
additional heatmaps showing significant changes between iDC-to-mature DC (mDC) , and iMAC-to-mature MAC (mMAC) maturation. The heatmaps
include all the genes displaying significant expression changes (>2-fold or <0.5-fold change; p < 0.01 and false discovery rate < 0.05). A scale is shown
at the bottom, wherein expression values range from −3 (lower expression levels, blue) to +3 (higher expression levels, red). b Venn diagrams showing
the degree of overlap of genes upregulated and downregulated between MO-to-iDC and MO-to-iMAC differentiation and iDC-to-mDC and iMAC-to-
mMAC activation. c Scatterplots showing the relationship between the log2-transformed fold change (FC) in expression and the log2-transformed FC
in DNA methylation. d Correlation between DNA methylation and expression data (the mean value for all CpG sites within a given sequence region is
shown) for all the significantly demethylated genes organized by genomic location [intergenic, promoter (1,500 and 200 upstream of the transcription
start site (TSS), 5′ untranslated region (UTR), first exon, gene body, and 3′UTR)]. e Box-plots representing the DNA methylation and expression values of
all genes that are demethylated during DC and MAC differentiation and whose upregulation is stronger in the maturation step than in the previous
differentiation step. f Diagram showing the proportion of genes among the DC-specific, MAC-specific and those that are demethylated in both
processes with no significant changes in expression during the differentiation step and upregulated during the lipopolysaccharide (LPS)-dependent
activation step. g Time-course analysis of DNA methylation and expression in two selected genes (IL1B and CCL20) during DC and MAC differentiation/
maturation, among those displaying no changes in the differentiation step and a sharp increase in thematuration step. h Chromatin immunoprecipitation
assays in IL1B and CCL20with anti-histone H3K27me3 and anti-histone H3K9me3 inMOs, and in a time-course manner in differentiation to iDCs and iMACs,
as well asmDCs andmMACs (120 h + LPS). The Y-axis shows the relative enrichment in arbitrary units
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demonstrates the functional effects of PF-956980 in inhi-
biting DC differentiation.
The effect of PF-956980 was very specific to the im-
pairment of demethylation of DC-specific genes in DC
differentiation (Fig. 3d), and had little effect on the de-
methylation of MAC-specific genes in MAC differenti-
ation or in genes that are commonly demethylated in both
DC and MAC differentiation (Fig. 3d and Additional
file 8B). Interestingly, in the presence of JAK3 inhibitors
and under the conditions required for DC differentiation,
DNA methylation levels of genes that were specifically
demethylated in MO-to-iMAC differentiation resembled
those observed in the absence of IL-4, indicating that in-
hibition of the pathway downstream of IL-4 removed the
constraints on this set of genes towards their DNA de-
methylation under the standard conditions for DC differ-
entiation (Fig. 3d).
In general, the effects at the expression level were as
expected, and impaired DNA demethylation was associ-
ated with diminished overexpression of DC-specific
genes during differentiation. Most notably, we observed
impaired overexpression of genes that only underwent
expression changes in the maturation step, once DNA
demethylation had been inhibited through the action of
JAK3 inhibitors (Additional file 8C).
To explore the extent of the role of the IL-4-JAK3-STAT6
pathway in the acquisition of the DC-specific methylation
signature, we performed a new methylation profiling to test
the effects of inhibiting JAK3. A comparison of MOs with
MOs differentiated to iDCs and iMACs both in the pres-
ence and absence of the JAK3 inhibitor PF-956980 revealed
that the DNA methylation patterns of iDCs incubated with
PF-956980 cluster together with iMACs (Additional
file 8D). In other words, treatment with PF-956980 erases
the DC-specific signature, and renders a DNA demethyla-
tion pattern indistinguishable to that of iMACs (Fig. 3e).
The specific analysis of some of the previously studied
genes confirmed this effect (Additional file 8E).
To unequivocally test the potential causal relationship
between JAK3 and STAT6 in the demethylation of
DC-specific genes, we investigated the consequences of
ablating JAK3 and STAT6 expression in MOs. We down-
regulated JAK3 and STAT6 levels in MOs using transient
transfection experiments with siRNA cocktails that target
different sites for each of these two proteins in compari-
son with a control siRNA. Twenty-four hours after trans-
fection, we induced DC differentiation with GM-CSF/
IL-4. Under these conditions, we used a western blot to
check the effects on JAK3 and STAT6 levels 4 days after
GM-CSF/IL-4 stimulation of MOs. This method enabled
us to confirm that the STAT6 and JAK3 were downregu-
lated by close to 50 % and 20 % (Fig. 3f), respectively. As a
result, we observed a noticeable shift of the surface DC
markers CD209 and CD83 (Additional file 9A).
We then checked the effects of JAK3 and STAT6 deple-
tion on the demethylation of DC-specific, MAC-specific
and DC/MAC common genes. Similar to the results ob-
tained from the pharmacological inhibition of JAK3,
siRNA-mediated depletion of JAK3 and STAT6 very specif-
ically impaired the demethylation of DC-specific genes in
DC differentiation (Fig. 3g) and had little effect on the de-
methylation of MAC-specific genes in MAC differentiation
(Additional file 9B) or in genes that are commonly
demethylated in both DC and MAC differentiation. These
results not only confirmed the participation of JAK3, down-
stream to IL-4, in the demethylation of DC-specific genes,
but also the participation of STAT6, the target of JAK3.
Constitutively activated STAT6 induces demethylation of
DC-specific genes during GM-CSF-only differentiation
To further investigate the potential direct involvement of
STAT6 in the demethylation of DC-specific genes, we per-
formed chromatin immunoprecipitation (ChIP) assays with
STAT6. We found that STAT6 did interact specifically with
DC-specific genes like DUOX1 and SLAMF1 in DC differ-
entiation (Fig. 4a), whilst there was no binding of these
genes during MAC differentiation. Interestingly, pharmaco-
logical inhibition of JAK3 led to impaired binding of STAT6
in DC-specific genes (Fig. 4a), reinforcing the notion of the
dependence on IL-4 and JAK3 for this interaction. We then
(See figure on previous page.)
Fig. 3 The IL-4-JAK3-STAT3 pathway has a direct role in targeting DNA demethylation in specific dendritic cell (DC) genes. a Diagram depicting
the pathway downstream of IL-4, including IL-4 receptor (IL-4R), JAK3 and STAT6. IL-4 is able to activate and translocate STAT6 transcription factor
to the nucleus, through STAT6 phosphorylation by JAK3 kinase. b Western blot assay confirming the presence of JAK3 and STAT6 in all cell types
studied and the exclusive existence of the phosphorylated form of STAT6 in DCs. Inhibitor PF-956980 at a concentration of 400 and 1,000 nM
throughout the entire differentiation process is able to prevent STAT6 phosphorylation. c Effects of PF-956980 on CD209 and CD14 in both granulocyte
macrophage colony-stimulating factor (GM-CSF)/IL-4-stimulated and GM-CSF-stimulated cells at 96 h, as measured by fluorescence-activated cell
sorting. d Effects of JAK3 inhibition by PF-956980 on DNA methylation over time in DC (GM-CSF/IL-4) differentiation, focusing on two DC-specific
genes (left), macrophage (MAC)-specific genes (centre) and two genes demethylated in both DC and MAC differentiation (right). e Heatmap showing
the effect in DNA methylation of JAK3 inhibition by PF-956980. This treatment is able to erase the DC-specific methylation signature in monocytes
(MOs) treated with GM-CSF/IL-4. f Western blot assays showing levels of STAT6, phospho-STAT6 and JAK3, 96 h after treatment with GM-CSF/IL-4 and
transfection with siRNA for STAT6. B-actin has been used as loading control. g Effects of siRNA against STAT6 (left panel) and JAK3 (right panel) on DNA
methylation changes over time focusing on two DC-specific genes (top), MAC-specific genes (middle) and two genes demethylated in both DC and
MAC differentiation (bottom). DMSO dimethyl sulfoxide, iDC immature dendritic cells, iMAC immature macrophage, LPS lipopolysaccharide
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Fig. 4 (See legend on next page.)
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investigated whether STAT6 interacts with TET2, either
directly or through other intermediates such as PU.1. How-
ever, we were unable to identify any direct interaction be-
tween STAT6 and TET2 (not shown). It should be noted
that these experiments are technically challenging, and such
an interaction cannot be fully discounted. An alternative
mechanism may be provided if STAT6 recruits PU.1, which
has in turn been proven to recruit TET2 [9] in a related
MO differentiation process. In fact, synergism between
STAT6 and PU.1 has been previously shown [25]. To test
whether PU.1 participates in demethylating these genes, we
also performed siRNA experiments against PU.1. We deter-
mined that PU.1 downregulation also impairs demethyla-
tion of some of these genes, although in a less specific
manner than STAT6. In addition, we also observed an
effect on the surface markers of both DCs and MACs
(Additional file 10).
To conclusively establish the role of IL-4/JAK3-
dependent demethylation of DC-specific genes via STAT6,
we performed gain-of-function experiments in MOs stimu-
lated exclusively with GM-CSF and transfected with a con-
stitutively activated form of STAT6. STAT6VT carries two
amino acid changes in the SH2 domain that affect the over-
all structure and stability of the monomeric and dimeric
protein [26] (Fig. 4b). When overexpressed in mammalian
cells, STAT6VT undergoes tyrosine phosphorylation; is
translocated to the nucleus (Fig. 4c), where it binds DNA;
and activates transcription in an IL-4-independent manner.
We infected MOs with a green fluorescent protein (GFP)-
expressing lentiviral MIG vector (pCDH-MIG) containing
STAT6VT and, in parallel, an empty GFP-expressing MIG
vector as a negative control. Following infection, we stimu-
lated cells with GM-CSF in the absence of IL-4, that is,
under our conditions for MAC differentiation. Infection of
MOs with the GFP-expressing empty vector achieved
higher levels than those with STAT6VT GFP vector, prob-
ably due to the lower titre of lentiviruses containing a larger
construct (Fig. 4d). In any case, we were able to isolate GFP
+ cells in both conditions, following 9 days after GM-CSF
stimulation. Not surprisingly, the ectopic expression of
STAT6VT resulted in increased levels of the DC-specific
marker DC-sign, following GM-CSF stimulation and in the
absence of IL-4 (Fig. 4e). We then performed bisulfite pyro-
sequencing of DC-specific and MAC-specific genes and
found that STAT6VT overexpression was able to induce
demethylation of DC-specific genes, such as DUOX1 and
SLAMF1, by-passing IL-4R upstream signalling (Fig. 4f). In
addition, the MAC-specific genes CCL20 and ARSB, which
are normally demethylated in the presence of GM-CSF, did
not become demethylated under the presence of STAT6VT
(Fig. 4f ), strongly indicating that STAT6 prevents
their demethylation under the conditions of DC dif-
ferentiation. In contrast, genes that were demethylated
under our standard DC and MAC differentiation con-
ditions (like CCL22 and CSF1R) were not affected by
the overexpression of STAT6VT. In summary, STAT6
is not only responsible for demethylating DC-specific
genes but also for preventing demethylation of MAC-
specific genes.
Altogether, our results demonstrate a direct relationship
between the extracellular stimulation through IL-4 leading
to MO-to-DC differentiation and the acquisition of DC-
specific DNA methylation and expression patterns, to-
gether with the inhibition of MAC-specific genes.
Moreover, we prove the role of the IL-4-JAK3-STAT6
pathway in instructing the cell epigenome to engage a spe-
cific differentiation state towards DCs, at the expense of
MAC differentiation.
Discussion
Our results identify for the first time the sequence of events
that occur downstream of a cytokine when instructing spe-
cific TET2-mediated active DNA demethylation associated
with the differentiation of effector cells of the innate im-
mune response. Specifically, we have established that IL-4
targets a demethylation signature of a specific subset
of genes in DC differentiation (and also prevents de-
methylation of inappropriate MAC-specific genes) in
(See figure on previous page.)
Fig. 4 Direct involvement of STAT6 in targeting DNA demethylation in specific dendritic cell (DC) genes. a Chromatin immunoprecipitation assays
confirm STAT6 binding to two genes (DUOX1, SLAMF1) that become specifically demethylated in DC differentiation. The panel also shows the loss
of STAT6 to DC-specific genes following treatment with JAK3 inhibitor PF-956980. Lack of binding of STAT6 under the conditions of macrophage
(MAC) differentiation (also in the presence of PF-956980) is also shown. b Diagram showing STAT6 gene domains and the double mutant that
mimics phosphorylated STAT6 (STAT6VT) and leads to a gain of function. c Western blot of 293 T cells transfected with wild-type STAT6 (STAT6
WT) and the activating double mutant STAT6VT showing the presence of the protein in the cytosolic or nuclear fraction. d Fluorescence-activated
cell sorting analysis showing the green fluorescent protein (GFP) labelling of cells infected with a GFP-expressing lentiviral MIG vector (pCDH-MIG)
containing STAT6VT (right panel) and empty GFP-expressing MIG vector as a negative control (left panel). e CD209 mean fluorescence measured
by flow cytometry in monocytes (MO) infected with STAT6 VT and the MOCK control vector after 9 days of culture with granulocyte macrophage
colony-stimulating factor (GM-CSF). Analysis was done by setting a gate to select cells with high GFP expression. f Effects on the DNA methylation
levels of two DC-specific genes in MOs treated with GM-CSF for 48 h followed by infection with mock or STAT STAT6V. Both the GFP+ and
GFP− fractions are shown. Examples of two DC-specific genes (left), MAC-specific genes (middle) and two genes demethylated in both DC and
MAC differentiation (right) are shown. g Model depicting the participation of the IL-4-JAK3-STAT6 pathway in targeting demethylation of
DC-specific genes
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a STAT6-dependent manner, providing a direct causal re-
lationship between external stimulation by this cytokine
and the targeted epigenetic changes that are necessary for
the acquisition of identity. These changes, as well as the
majority of DNA methylation changes in DC and MAC
differentiation, occur during the differentiation step from
MOs, before LPS-induced maturation. The direction of
DNA methylation changes in DC and MAC, as well as
their occurrence during the differentiation step, contrast
with the expression changes that occur in both steps and
both directions (upregulation and downregulation). We
have identified a set of genes in which DNA demethy-
lation precedes their upregulation, indicating that DNA
demethylation prepares those genes for subsequent over-
expression during the maturation step.
In accordance with the findings of others [6], diffe-
rentiation from MOs to DCs and from MOs to MACs is
associated with a predominant occurrence of DNA de-
methylation. Conversely, very few DNA demethylation
changes occur during the activation of these two cell types
when exposed to LPS, which activates these cells to re-
spond through TLR4 and CD14. The predominance of
demethylation changes differs from the direction of
changes in a related model, specifically the M-CSF/
RANKL-mediated differentiation of MOs to OCs, in which
gains of both DNA methylation and demethylation occur
to a similar extent [9]. As in the cases of MO-to-DC and
MO-to-MAC differentiation, demethylation in OC differen-
tiation takes place through active mechanisms [6, 9] and
occurs to a similar extent. In contrast, unlike in DC and
MAC differentiation, where gain of DNA methylation is re-
stricted to a few genes, thousands of CpG sites become
hypermethylated in OC differentiation. It is likely that the
widespread occurrence of deposition of DNA methylation
in OC differentiation is due to the fact that OC differenti-
ation takes place over a few weeks. It is also remarkable that
the vast majority of DNA demethylation events in DC and
MAC differentiation/maturation occur in the differentiation
step and that only a few changes take place during the mat-
uration of these cells following exposure to LPS. If DNA
methylation changes have an effect on the stability of cell
identity, it might simply reflect that this control is more im-
portant in the initial differentiating step, from MOs to
iDCs/iMACs, as it also prepares those cells and their chro-
matin for a potentially rapid response to fulfil their function
in immunity in case of an insult.
The gene expression data show that large changes in up-
regulation and downregulation occur in the differentiation
and maturation steps, reflecting the activation of specific
response transcriptional programmes. In a general way,
demethylation is associated with transcriptional activation,
whereas gain of methylation is often associated with gene
silencing. Although the current view is now more complex
and involves different types of relationship between DNA
methylation and expression status, our data on MO-to-
DC and MO-to-MAC differentiation also show an associ-
ation between demethylation and gene activation that is
particularly evident in demethylated CpGs near the TSS
and the first exon of genes. Identifying genes displaying
both demethylation and overexpression during differenti-
ation revealed an enrichment of genes relevant to DC/
MAC function. However, it is of particular note that there
is a set of genes that undergo large changes in gene ex-
pression (particularly genes that become overexpressed)
only during the maturation step, although their demethyl-
ation occurred previously, during differentiation. It is as if
their demethylation were a prerequisite for their subse-
quent overexpression, and a second signal were needed ul-
timately to trigger the activation once the unmethylated/
competent status has been achieved. This separation be-
tween demethylation and overexpression in the differenti-
ation and maturation steps may constitute a mechanism
to facilitate a rapid response following activating stimuli,
such as an encounter with a bacterial antigen, while keep-
ing a threshold that prevents improper triggering. In this
respect, demethylation preceding stimuli-mediated activa-
tion may act both as a gate-keeper and a facilitator of
stimulus-dependent gene expression. A preparation of the
genome in non-cycling cells has recently been described
in naïve B cells, whereby single-stranded DNA sequencing
experiments showed that most of the genome is poised
for antigen-driven activation [27].
Comparing two in vitro differentiation models that only
differ in the participation of the cytokine IL-4 allowed us
to directly assess IL-4’s involvement in the DNA methy-
lation changes underlying the fine-tuning of cell fate
acquisition. Differentiation to DCs and MACs involves de-
methylation of a large common set of genes, while other
CpGs become demethylated in a DC-specific and MAC-
specific manner. The acquisition of DC or MAC fate in
our model differed only with respect to exposure to IL-4,
so we reasoned that the difference is largely determined
by events downstream of IL-4R. It is conceivable that IL-
4-dependent cell specification of DC identity relies not
only on determining which genes are specifically demethy-
lated in DCs, but also on preventing demethylation of
those that are specifically demethylated in MAC differen-
tiation. It was reported some time ago that IL-4 inhibits
the production of tumour necrosis factor alpha (TNF-ɑ),
IL-1 and prostaglandin E2 in human MOs [28] in a
STAT6-dependent and a STAT6-independent manner
[29]. Our results could provide molecular evidence of such
inhibition, given that IL-1a, IL-1b and TNF all become
demethylated in our system.
Human MOs bind IL-4 to membrane-bound dimeric
IL-4R, which consists of the IL-4Rɑ chain that recog-
nizes IL-4 with high affinity [30], and a second chain
that forms either Type I (with γc chain) or Type II
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receptors (with IL-13Rɑ1). Upon dimerization, signal
transduction leads to the activation of several routes,
with STAT6 activation and translocation to the nucleus
following JAK3-mediated phosphorylation as a hallmark
[31]. Our study has shown that the IL-4-JAK3-STAT6
pathway plays a major role in the specific methylation
changes that drive DC differentiation (Fig. 4g). We have
demonstrated that JAK3 and STAT6 downregulation im-
pairs DC-specific demethylation and that the ectopic ex-
pression of a constitutively activated/nuclear form of
STAT6 leads to specific demethylation of DC genes
under the conditions of MAC differentiation (in the
absence of IL-4). These results suggest a direct role of
IL-4-JAK3-STAT6 in promoting specific demethylation
and subsequent activation of a subset of DC genes, as
well as impairing the demethylation of MAC-specific
genes. The inhibitory effect of STAT6 has been de-
scribed in Th2 differentiation of human T cells in which
STAT6 regulates the expression of around 80 % of IL-4-
responsive genes [32]. Our results are in line with a re-
cently proposed model of asymmetric participation of
different STATs in response to combinations of cyto-
kines, which strongly suggests that in response to two
cytokine signals, one STAT may provide a wider tran-
scriptional programme that is restricted to gain specifi-
city by the superimposed action of another STAT [33].
In the present work, we extend this notion to epigenetic
regulation, in particular, DNA methylation.
Given the participation of TET2 in the active demeth-
ylation of DC and MAC differentiation, as shown in this
study, it seemed likely that STAT6 would recruit this en-
zyme. However, immunoprecipitation experiments were
unable to demonstrate such interaction. Because PU.1
has been shown to associate and recruit TET2 to genes
that become demethylated [9], and also interacts with
STAT6 [25], a possible scenario could involve STAT6 re-
cruitment of PU.1-TET2 to genes that become specific-
ally demethylated in DCs (Fig. 4g). It is likely that other
TFs also participate in this process. In fact, there are
various connections and mechanisms that associate
DNA methylation changes with TF binding [34]. Our
analysis of the enrichment of TF-binding motifs near
demethylated CpGs supports this notion: some of them,
like the GATA1 binding motif, are specifically enriched
in genes demethylated in DCs, whereas C/EBPα/β, MITF,
NANOG and CREB are enriched at the demethylated sites
in iMAC differentiation. However, the participation of
these factors in DNA methylation could also be indirect.
It will be interesting to establish whether STAT6, or any
other additional TF, is able to directly recruit TET pro-
teins to the sites undergoing DNA demethylation.
The finding that a cytokine like IL-4 drives the DNA
demethylation of specific sets of genes that are crucial
for DC versus MAC identity and function opens up a
number of possibilities from the fundamental and trans-
lational points of view, as new targets for pharmaco-
logical intervention of innate immune cell responses.
Conclusions
In the present study, we have compared the DNA methy-
lation changes during human MO-to-DC and MO-to-
MAC differentiation, in which IL-4 represents the sole
differential factor determining DC versus MAC fate. Our
data reveal the existence of both common and cell-type
specific DNA demethylation of many genes, and that such
DNA demethylation depends on TET2 and is essential for
the acquisition of proper DC and MAC identity. We dem-
onstrate that upon IL-4R engagement by its ligand, activa-
tion of the JAK3-STAT6 pathway leads to the acquisition
of DC-specific demethylation and expression profiles, by
activating DC-specific genes and repressing MAC-specific
genes. Furthermore, we show that IL-4R signalling can be
bypassed with the introduction of a constitutively acti-
vated STAT6 form that instructs DC-specific methylation
changes in the absence of IL-4. In summary, our results
constitute the first report of a cytokine-mediated down-
stream sequence of events that leads to direct gene-specific
demethylation in innate immune cell differentiation.
Methods
Differentiation of DCs and MACs from peripheral blood
mononuclear cells
Human samples (blood) used in this study came from
anonymous blood donors and were obtained as buffy
coats from the Catalan Blood and Tissue Bank (Banc de
Sang i Teixits) in Barcelona. The anonymous blood do-
nors received oral and written information about the
possibility that their blood would be used for research
purposes, and any questions that arose were then an-
swered. Before providing the first blood sample, all do-
nors signed a consent form at the Banc de Sang. The
Banc de Sang follows the principles set out in the WMA
Declaration of Helsinki. The protocol used to isolate and
differentiate cells from these anonymous donors was
approved by the Ethics Committee of the University
Hospital of Bellvitge (CEIC) on 28 May 2011 (and reno-
vated on 4 December 2014).
The blood was carefully layered on a Ficoll–Paque gradi-
ent (Amersham, Buckinghamshire, UK) and centrifuged at
2,000 rpm for 30 min without braking. Peripheral blood
mononuclear cells (PBMCs), from the interface between
the plasma and the Ficoll–Paque gradient, were then col-
lected and washed twice with ice-cold phosphate-buffered
saline (PBS), followed by centrifugation at 2,000 rpm for
5 min. Pure MOs were isolated from PBMCs using positive
selection with MACS magnetic CD14 antibody (Miltenyi
Biotec, Bergisch Gladbach, Germany). Cells were then re-
suspended in RPMI Medium 1640 (1×) +GlutaMAXTM-1
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(Gibco, Thermo Fisher Scientific, Waltham, MA, USA Life
Technologies) containing 10 % foetal bovine serum, 100
units/mL penicillin, 100 μg/mL streptomycin and antimy-
cotic. For DC differentiation, the medium was supple-
mented with 500 U human IL-4 and 800 U GM-CSF
(Gentaur Molecular Products, Kampenhout, Belgium). For
MAC differentiation, the medium was supplemented with
800 U GM-CSF (Gentaur Molecular Products, Kampenh-
out, Belgium).
Depending on the amount needed, cells were seeded
at a density of 3 × 105 cells/well in 96-well plates, 5 × 106
cells/well in 6-well plates, or 40 × 106 cells in 10-mm
plates and cultured for 4 days (unless otherwise noted);
medium and cytokines were changed every 2 days. On
day 4, cell maturation was induced by culturing cells
with 5 μG/ml LPS (Sigma-Aldrich, St. Louis, MI, USA)
for 24 h.
The presence of DCs and MACs was checked at the
protein level by flow cytometry (Gallios Flow Cytometer,
Beckman Coulter) and analysed with FlowJo software
(Tree Star, Inc., San Carlos, CA, USA), testing for the
upregulation of specific DC markers CD209 conjugated
to V450 (BD Horizon, BD Biosciences, Franklin Lakes,
NJ, USA), and maturation DC marker CD83 conjugated
to APC (Miltenyi Biotec). Expression of CD14 (Miltenyi
Biotec), which was high for MOs, medium for MACs
and low for DCs, was also confirmed. MACs and DCs
were also analysed at the mRNA level with respect to
the upregulation of MO marker CD14 and the following
key DC and MAC markers: CD206, CD209, CD86,
CD83, MSR1 and CXCL13.
DNA methylation profiling using universal bead arrays
Infinium HumanMethylation450 BeadChips (Illumina,
Inc., San Diego, CA, USA) were used to analyse DNA
methylation. This array allows >485,000 methylation
sites per sample to be interrogated at single-nucleotide
resolution. This encompasses 99 % of RefSeq genes, with
an average of 17 CpG sites per gene region distributed
across the promoter, 5′UTR, the first exon, the gene
body and 3′UTR. It covers 96 % of CpG islands, with
additional coverage in CpG island shores and the regions
flanking them. DNA samples were bisulfite-converted
using the EZ DNA methylation kit (Zymo Research, Or-
ange, CA, USA). After bisulfite treatment, the remaining
assay steps were performed following the specifications
and using the reagents supplied and recommended by
the manufacturer. The array was hybridized using a
temperature gradient programme, and arrays were im-
aged using a BeadArray Reader (Illumina Inc.,San Diego,
CA, USA). The image processing and intensity data ex-
traction software and procedures were as previously de-
scribed [9]. Each methylation data point is obtained
from a combination of the Cy3 and Cy5 fluorescent
intensities from the M (methylated) and U (unmethy-
lated) alleles. Background intensity computed from a set
of negative controls was subtracted from each data
point. For representation and further analysis we used
beta and M values [35]. The beta value is the ratio of the
methylated probe intensity to the overall intensity (the
sum of the methylated and unmethylated probe inten-
sities). The M value is calculated as the log2 ratio of the
intensities of the methylated versus unmethylated probe.
Beta values range from 0 to 1 and make intuitive sense.
They were used to derive heatmaps and for comparisons
with DNA methylation percentages from bisulfite pyro-
sequencing experiments. However, for statistical pur-
poses, the use of M values is more appropriate.
Detection of differentially methylated CpGs
The approach to selecting differentially methylated CpGs
was implemented in the statistical language R. To process
Illumina Infinium HumanMethylation450 methylation
data we used the methods available in the limma, gene-
filter and lumi packages, which are accessible from the
Bioconductor repository. Before statistical analysis, a pre-
processing stage was applied, the main steps being: (1)
colour balance adjustment, that is, normalization between
two colour channels; (2) quantile normalization based on
colour balance-adjusted data; and (3) variance filtering by
interquartile range using 0.50 as the threshold value. Re-
sults were analysed using an eBayes moderated t-statistical
test carried out with the limma package [5]. Specifically, a
paired limma was performed as implemented in the IMA
package [6]. Several criteria have been proposed to repre-
sent significant differences in methylated CpGs. In this
study, we considered a probe to be differentially methyl-
ated if it had shown a >2-fold (hypermethylation) or <0.5-
fold (hypomethylation) difference, and if the statistical test
was significant (p < 0.01 and FDR < 0.05), using M values
for the statistical analysis and cut-off. For candidate gene
selection we added the requisite that the difference of beta
values was at least 20 %.
Bisulphite sequencing and pyrosequencing
Bisulphite pyrosequencing was used to validate CpG
methylation changes resulting from the analysis with the
Infinium HumanMethylation450 BeadChips. Bisulphite
modification of genomic DNA isolated from MOs, DCs
and MACs was performed using standard methods. Oxi-
dative bisulfite modifications were performed as described
recently by Booth and colleagues [36]. The time course
was measured in biological triplicates. Briefly, 2 μl of the
converted DNA (corresponding to approximately 20–
30 ng) were used as a template in each subsequent PCR.
Primers for PCR amplification and sequencing were de-
signed with the PyroMark® Assay Design 2.0 software
(Qiagen, Hilden, Germany). PCRs were performed with
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the HotStart Taq DNA polymerase PCR kit (Qiagen, Hil-
den, Germany), and the success of amplification was
assessed by agarose gel electrophoresis. PCR products
were pyrosequenced with the PyromarkTM Q24 system
(Qiagen, Hilden, Germany). All primer sequences are
listed in Additional file 11.
Gene ontology analysis
GO analysis was performed using the FatiGO tool,
which uses Fisher’s exact test to detect significant over-
representation of GO terms in one of the sets (list of se-
lected genes) with respect to the other (the rest of the
genome). We applied multiple test correction to take
into account multiple hypothesis testing (one hypothesis
for each GO term), reducing the possibility of false-
positive results. GO terms with adjusted values of p <
0.05 were considered significant.
Analysis of TF binding
We used meme tool and the TRANSFAC database to
identify STAT6 binding motifs in the 1,000 base pair re-
gion upstream and downstream of the centre of hypo-
methylated CpG sites. ChIP primers were designed for
the areas flanking those regions.
Expression array
Expression studies were performed using the Affymetrix
platform according to manufacturer’s instructions. Briefly,
1 μg total RNA was extracted with Trizol from MOs, DCs
and MACs, and hybridized to an Affymetrix Human
Prime View Array (Affymetrix Inc., Santa Clara, CA,
USA). Probe intensity normalization and downstream
analysis were obtained using statistical analysis language R
in combination with Bioconductor repository functions
(http://bioconductor.org). Normalized data obtained with
the “affy” package algorithm vsnrma [37] was followed by
probe identity filtering, under strong statistical confidence
thresholds (p-value < 0.01; adjusted p value (BH) < 0.05;
FC < 2 & FC > 2 for downregulated and upregulated re-
spectively). Finally, comparison of expression and DNA
methylation data were performed by applying custom R
scripting.
Graphs and heatmaps
All graphs were created using Prism5 Graphpad. Heat-
maps of the expression or methylation data were gener-
ated using the Genesis program (Graz University of
Technology, Graz, Austria).
BrdU proliferation assays
BrdU was used at a final concentration of 300 μM, as pre-
viously described [9]. BrdU pulsing solution was added to
each well at days 2 and 4. For flow cytometry assays,
CD14+ cells were seeded in 6-well plates and cultured in
differentiation media. BrdU was added to the medium
at different times and after 2 days cells were fixed (4 %
paraformaldehyde, 30 minutes, room temperature),
permeabilized (PBS-bovine serum albumin-Triton X-100
0.8 %, 10 min, room temperature), and treated with HCl
2 N for 30 min. After DNA opening, HCl was neutralized
by two 5-min washes with NaBo (0.1 M, pH 8.5) and two
5-min washes with PBT (PBS-bovine serum albumin-
Triton X-100 0.8 %). Cells were incubated with anti-
BrdU antibody (18 h at 4 °C, 1:1,000 dilution) and an
anti-mouse Alexa-488 conjugated antibody was added
to detect the BrdU-positive nuclei.
Transfection of primary human MOs
We used ON-TARGETplus siRNAs against STAT6, JAK3
and TET2 to perform knockdown experiments in pe-
ripheral blood MOs. We also used ON-TARGETplus
Non-targeting Control Pool as a negative control. For
PU.1 silencing experiments, two different Silencer® select
pre-designed siRNAs against human PU.1 (one targeting
exon 2 and another targeting the 3′UTR) and a Silencer®
select negative control were used. We transfected MOs
with siRNAs using Lipofectamine 3000 Reagent (Thermo
Fisher Scientific Co., Carlsbad, CA, USA) and added cyto-
kines 24 h later. We refreshed the transfection 3 days after
starting the culture. We examined the levels of the target
proteins by western blot 2 and 4 days after siRNA trans-
fection. Three biological replicates of the experiments
were performed.
Chromatin immunoprecipitation assays
For ChIP assays, CD14+ cells (MOs) treated with IL-4/
GM-CSF for 0 and 2 days were crosslinked with 1 % formal-
dehyde and subjected to immunoprecipitation after sonic-
ation. ChIP experiments were performed using a low cell
ChIP kit (Diagenode SA, Seraing, Belgium). They were ana-
lysed by real-time quantitative PCR. Data are represented
as the ratio of the bound fraction to the input for each spe-
cific factor. We used an antibody against STAT6 (Santa
Cruz, sc-981x), and histone marks H3K9me3 (Abcam,
ab8898) and H3K27me3 (Millipore 07-449). Human IgG
was used as a negative control. Primer sequences were
designed to contain predicted or known TF binding (from
TRANSFAC or ChIPseq data) as close as possible to the
CpG undergoing methylation changes. Primer sequences
are shown in Additional file 11. Three biological
replicates of the experiments were performed.
Inhibition of the JAK3
JAK3 was pharmacologically inhibited using the specific
inhibitor PF-956980 [24] (Sigma) following the manufac-
turer’s instructions. MOs were pre-treated for 1 h with
PF-956980 on day 0 of differentiation. Following pre-
incubation, MO differentiation was induced with IL-4/
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GM-CSF or GM-CSF alone in the presence of PF-
956980.
STAT6 constructs, generation of lentiviral supernatants
and cellular transduction
We amplified the STAT6 coding DNA sequence using
PCR with AccuPrime Pfx high-fidelity DNA Polymerase
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA)
following the manufacturer’s instructions. A reverse primer
containing an HA tag was introduced in the sequence N-
terminal end. The double mutant STAT6VT was prepared
by point mutagenesis using PCR to introduce two alanine
residues at amino acid positions 547/548. Sequences were
subcloned in pCDH-MIG vector and verified by
sequencing.
Two culture supernatants were generated by transient
transfection of 293FT cells and were collected 48 and 72 h
post-transfection. The first supernatant contained the
pMSCV-GFP (mock) or the pMSCV-GFP-STAT6VT, and
the second supernatant contained the SIVmac-derived
helper particles that pack the Vpx protein able to degrade
SAMHD1 [38]. Viral supernatants were concentrated × 10
by ultracentrifugation at 20,000 rpm at 4 °C for 2 h using
Sorvall centrifuge (Thermo Scientific) and fresh MOs
were infected with both viral supernatants. Infected MOs
were cultured with GM-CSF for 9 days at 37 °C. The
media was refreshed every 2 days. GFP-positive cells were
sorted in a MoFlo Astrios (Beckman Coulter, Brea, CA,
USA), lysed in Proteinase K buffer and incubated over-
night (ON) at 65 °C. Genomic DNA was isolated by stand-
ard phenol-chloroform extraction for bisulphite
pyrosequencing.
Data Access
Methylation array and expression array data for this publi-
cation have been deposited in the NCBI Gene Expression
Omnibus and are accessible through GEO Series acces-
sion number: [GEO: GSE71837] (methylation data for DC
and MAC differentiation, corresponding to Fig. 1c), [GEO:
GSE75937] (methylation data for DC and MAC differenti-
ation in the presence of JAK3 inhibitors, corresponding to
Fig. 3e) and [GEO: GSE75938] (expression data corre-
sponding to Fig. 2a).
Additional files
Additional file 1: (A) DC and MAC markers, checked by quantitative
RT-PCR. Upregulation of DC and MAC markers CD209, CD83, MSR1,
CXCL13, CD206, CD86 and downregulation of monocyte marker CD14
were detected. (B) Specific DC and MAC surface markers analysed by
flow cytometry. The CD14 receptor is high in MOs, intermediate in MACs
and low/negative in DCs. CD209 is a DC marker; CD206 is positive in DCs
and MACs; CD83 is increased in mDCs; CD86 is increased in mMACs. The
percentage of positive cells for each marker is indicated in each graph.
Because CD83 and CD86 are also present in the immature cells, we have
established ‘highly positive cells’ once a significant shift is observed, and
a second percentage is indicated for those highly positive cells (bottom).
(C) BrdU assay showing absence of proliferation during dendritic and
macrophage differentiation. (PDF 113 kb)
Additional file 2: List of hypomethylated and hypermethylated
genes during MO to DC and MAC differentiation and maturation
(>2-fold or <0.5-fold change; p < 0.01 and FDR < 0.05). Difference of
β values are indicated for each gene. (XLSX 1035 kb)
Additional file 3: (A) Scatterplots showing DNA methylation profiles
of matching pairs (MO-iDC; MO-iMAC; iDC-mDC; iMAC-mMAC). CpGs
with significant differences (>2-fold change or <0.5-fold change; p < 0.01
and FDR < 0.05) in average results for three samples are highlighted in blue
(DCs) or red (MACs). The x-axis and y-axis of each graph correspond to the
β values for each paired comparison, as indicated in the lower left corner.
(B) A Venn diagram showing the overlap between Zhang et al. [17] data
and our own data corresponding to the list of demethylated genes in
MO-to-iDC differentiation. (C) Technical validation of the array data by
bisulfite pyrosequencing of modified DNA. Three groups of genes are
represented: demethylated genes specific to iDC differentiation, demethylated
genes specific to iMAC differentiation, and genes that are commonly
demethylated in iDC and iMAC differentiation. (D) 5hmC content in several
of the CpGs that are rapidly demethylated after cytokine addition to MOs.
(PDF 1037 kb)
Additional file 4: Selected DC-specific (blue), MAC-specific (red) and
common to DC and MAC (grey) demethylated genes during DC and
MAC differentiation. (DOCX 22 kb)
Additional file 5: Role of TET2 in DNA demethylation and
acquisition of DC phenotype. (A) Flow cytometry analysis of CD14,
CD209 and CD83 in DCs and MACs transfected with an siRNA against
TET2, and their corresponding siRNA negative control. (B) Time-course
analysis of the effects of TET2 silencing on DNA methylation changes
during both DC (right panel) and MAC (left panel) differentiation. Specific
DC (upper panel), MAC (bottom panel) and common (bottom panel)
genes for both DC and MAC differentiation were analysed. (PDF 23 kb)
Additional file 6: Relationship between methylation and expression
changes in MAC and DC differentiation. “Poised” genes are those
undergoing DNA methylation changes at the differentiation stage and
expression changes only at the activation stage. (XLSX 640 kb)
Additional file 7: (A) DNA methylation dynamics of selected loci
during MO-to-DC and MO-to-MAC differentiation and maturation.
Methylation percentage determined by bisulfite pyrosequencing. (B) RNA
expression dynamics of selected loci during MO-to-DC and MO-to-MAC
differentiation and maturation. Quantitative RT-PCR data relative to HPRT1
and RPL38. (C) ChIP assays of IL1A (MAC-specific) and AIM2 (common;
displaying higher LPS-mediated upregulation in MACs) with anti-histone
H3K27me3 and anti-histone H3K9me3 in MOs, and in a time-course
manner in differentiation to iDCs and iMACs, as well as mDCs and
mMACs (120 h + LPS). (PDF 54 kb)
Additional file 8: (A) Surface DC and MAC markers analysed by
flow cytometry during DC and MAC differentiation in the presence
of the inhibitor against JAK3 or the carrier (DMSO). (B) Effects of JAK3
inhibition on gene expression of specific DC genes regulated by DNA
methylation in DC and MAC population. Quantitative reverse transcriptase
polymerase chain reaction (RT-PCR) data relative to HPRT1 and RPL38. (C)
Effects of JAK3 inhibition by PF-956980 on DNA methylation over time in
MAC (GM-CSF) differentiation, focusing on two DC-specific genes (top),
MAC-specific genes (middle) and two genes demethylated in both DC and
MAC differentiation (bottom). (D) Cluster analysis showing the effects on
distance between samples following treatment with JAK3 inhibitor PF-
956980 on MOs exposed for 96 h to GM-CSF/IL-4 or GM-CSF alone. (E) Beta
values extracted from the high-throughput analysis of selected genes in
MOs, iDCs, and iMACs in the absence or presence of PF-956980. (PDF 57 kb)
Additional file 9: (A) Flow cytometry was used to detect surface
marker changes in siRNA experiments during DC (-si STAT6 and -si
JAK3) and MAC (-si STAT6) differentiation and maturation. A
negative control pool from Dharmacon was used as a control in all
experiments performed. (B) DNA methylation of MO transfected cells
with an siRNA against STAT6 and their negative control, in the absence
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of IL-4 during MO differentiation. (C) Gene expression consequences
measured by quantitative RT-PCR in DC, when STAT6 is inhibited by an
siRNA. (PDF 26 kb)
Additional file 10: PU.1. contributes to DNA demethylation.
(A) Western blot showing decrease in PU.1 levels by treating cells with
an –si against PU.1. (B) Analysis of DC phenotype (CD14, CD209 and
CD83 expression) during MO differentiation in PU.1-silenced cells. (C)
Time-course analysis of DNA methylation in cells treated with -si against
PU.1. DCs (right panel) and MACs (left panel) were analysed for specific
DC (upper panel), MAC and common (bottom panels) genes during
differentiation of MOs into both DCs and MACs. (PDF 26 kb)
Additional file 11: List of primers. (XLSX 14 kb)
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